Prognostic Factors in Patients Receiving Third Line Targeted Therapy for Metastatic Renal Cell Carcinoma

No AccessJournal of UrologyAdult Urology1 Jun 2015Prognostic Factors in Patients Receiving Third Line Targeted Therapy for Metastatic Renal Cell Carcinoma Roberto Iacovelli, Alessio Farcomeni, Cora N. Sternberg, Giacomo Cartenì, Michele Milella, Matteo Santoni, Linda Cerbone, Giuseppe Di Lorenzo, Elena Verzoni, Cinzia Ortega, Roberto Sabbatini, Riccardo Ricotta, Caterina Messina, Vito Lorusso, Francesco Atzori, Fabio De Vincenzo, Cosimo Sacco, Francesco Boccardo, Francesco Valduga, Francesco Massari, Valentina Baldazzi, Saverio Cinieri, Alessandra Mosca, Enzo Maria Ruggeri, Alfredo Berruti, and Giuseppe Procopio Roberto IacovelliRoberto Iacovelli Medical Oncology Unit 1, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy , Alessio FarcomeniAlessio Farcomeni Department of Public Health and Infectious Diseases, Sapienza-University of Rome, Rome, Italy , Cora N. SternbergCora N. Sternberg Department of Medical Oncology, San Camillo Forlanini Hospital, Rome, Italy , Giacomo CartenìGiacomo Cartenì Oncology Unit, A. Cardarelli Hospital, Naples, Italy , Michele MilellaMichele Milella Medical Oncology A, Regina Elena National Cancer Institute, Rome, Italy , Matteo SantoniMatteo Santoni Department of Medical Oncology, Polytechnic University of the Marche Region, Ancona, Italy , Linda CerboneLinda Cerbone Department of Medical Oncology, San Camillo Forlanini Hospital, Rome, Italy , Giuseppe Di LorenzoGiuseppe Di Lorenzo Medical Oncology, Genitourinary Cancer Section, University Federico II, Naples, Italy , Elena VerzoniElena Verzoni Medical Oncology Unit 1, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy , Cinzia OrtegaCinzia Ortega Fondazione del Piemonte per l'Oncologia IRCC, Candiolo, Italy , Roberto SabbatiniRoberto Sabbatini Oncology Division, Department of Oncology and Hematology, University of Modena e Reggio Emilia, Modena, Italy , Riccardo RicottaRiccardo Ricotta Falck Division of Oncology, Ospedale Niguarda Ca' Granda, Milan, Italy , Caterina MessinaCaterina Messina Oncology Division, Ospedali Riuniti, Bergamo, Italy , Vito LorussoVito Lorusso National Cancer Research Center, Istituto Tumori "Giovanni Paolo II", Bari, Italy , Francesco AtzoriFrancesco Atzori Medical Oncology Unit, Azienda Ospedaliero Universitaria of Cagliari, Cagliari, Italy , Fabio De VincenzoFabio De Vincenzo Oncology and Hematology Unit, Humanitas Cancer Center, Istituto Clinico Humanitas, Rozzano, Italy , Cosimo SaccoCosimo Sacco Oncology Unit, St Maria della Misericordia Hospital, Udine, Italy , Francesco BoccardoFrancesco Boccardo University and IRCCS AOU-San Martino-IST, National Cancer Research Institute, Genoa, Italy , Francesco ValdugaFrancesco Valduga Medical Oncology, St. Chiara Hospital, Trento, Italy , Francesco MassariFrancesco Massari Medical Oncology, "G.B. Rossi" Academic Hospital, University of Verona, Verona, Italy , Valentina BaldazziValentina Baldazzi Department of Medical Oncology; Santa Maria Annunziata Hospital, Florence, Italy , Saverio CinieriSaverio Cinieri Medical Oncology and Breast Unit Department, Sen A. Perrino Hospital, Brindisi, Italy , Alessandra MoscaAlessandra Mosca Medical Oncology, Maggiore della Carità University Hospital, Novara, Italy , Enzo Maria RuggeriEnzo Maria Ruggeri Oncology Unit, Belcolle Hospital, Viterbo, Italy , Alfredo BerrutiAlfredo Berruti Medical Oncology, University of Brescia, Brescia, Italy , and Giuseppe ProcopioGiuseppe Procopio Medical Oncology Unit 1, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy View All Author Informationhttps://doi.org/10.1016/j.juro.2014.11.092AboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract Purpose: Several prognostic models have been proposed for metastatic renal cell carcinoma but none has been validated in patients who receive third line targeted agents. We evaluated prognostic factors in patients with metastatic renal cell carcinoma who received a third line targeted agent. Materials and Methods: We retrospectively reviewed data on 2,065 patients with clear cell metastatic renal cell carcinoma who were treated with targeted therapy at a total of 23 centers in Italy. Included in final analysis were 281 patients treated with 3 targeted agents. Overall survival was the main outcome. Cox proportional hazards regression followed by bootstrap validation was used to identify independent prognostic factors. Results: Three clinical characteristics (ECOG performance status greater than 1, metastasis at diagnosis and liver metastasis) and 2 biochemical factors (hemoglobin less than the lower limit of normal and neutrophil count greater than the upper limit of normal, respectively) were prognostic. Patients were classified into 3 risk categories, including low—zero or 1, intermediate—2 and high risk—more than 2 risk factors. Median overall survival was 19.7, 10.1 and 5.5 months, and 1-year overall survival was 71%, 43% and 15%, respectively. The major limitation was the retrospective nature of this study and absent external validation. Conclusions: This nomogram included clinical and biochemical prognostic factors. In clinical trials it may be useful to select patients and define the prognosis. References 1 : Targeted therapies for renal cell carcinoma: understanding their impact on survival. Target Oncol2010; 5: 131. Google Scholar 2 : Overall survival in renal-cell carcinoma with pazopanib versus sunitinib. N Engl J Med2014; 370: 1769. Google Scholar 3 : Targeted therapies and complete responses in first line treatment of metastatic renal cell carcinoma. A meta-analysis of published trials. Cancer Treat Rev2014; 40: 271. Google Scholar 4 : Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J Clin Oncol1999; 17: 2530. Crossref, Medline, Google Scholar 5 : Validation and extension of the Memorial Sloan-Kettering prognostic factors model for survival in patients with previously untreated metastatic renal cell carcinoma. J Clin Oncol2005; 23: 832. Google Scholar 6 : Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study. J Clin Oncol2009; 27: 5794. Google Scholar 7 : Vascular endothelial growth factor-targeted therapy for the treatment of adult metastatic Xp11.2 translocation renal cell carcinoma. Cancer2010; 116: 5219. Google Scholar 8 : The International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) model as a prognostic tool in metastatic renal cell carcinoma (mRCC) patients previously treated with first-line targeted therapy (TT). J Clin Oncol2014; 32. abstract 398. Google Scholar 9 : Extensions of net reclassification improvement calculations to measure usefulness of new biomarkers. Stat Med2011; 30: 11. Google Scholar 10 : External validation and comparison with other models of the International Metastatic Renal-Cell Carcinoma Database Consortium prognostic model: a population-based study. Lancet Oncol2013; 14: 141. Google Scholar 11 : Clinical outcomes in patients receiving three lines of targeted therapy for metastatic renal cell carcinoma: results from a large patient cohort. Eur J Cancer2013; 49: 2134. Google Scholar 12 : Second line treatment of metastatic renal cell carcinoma: the Institut Gustave Roussy experience with targeted therapies in 251 consecutive patients. Eur J Cancer2013; 49: 1898. Google Scholar 13 : First-, second-, third-line therapy for mRCC: benchmarks for trial design from the IMDC. Br J Cancer2014; 110: 1917. Google Scholar 14 : Dovitinib versus sorafenib for third-line targeted treatment of patients with metastatic renal cell carcinoma: an open-label, randomised phase 3 trial. Lancet Oncol2014; 15: 286. Google Scholar 15 : Distribution of metastatic sites in renal cell carcinoma: a population-based analysis. Ann Oncol2012; 23: 973. Google Scholar 16 : Prognostic factors of survival and rapid progression in 782 patients with metastatic renal carcinomas treated by cytokines: a report from the Groupe Français d'Immunothérapie. Ann Oncol2002; 13: 1460. Google Scholar 17 : Impact of bone and liver metastases on patients with renal cell carcinoma treated with targeted therapy. Eur Urol2014; 65: 577. Google Scholar © 2015 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 193Issue 6June 2015Page: 1905-1910Supplementary Materials Advertisement Copyright & Permissions© 2015 by American Urological Association Education and Research, Inc.Keywordsrenal cellcarcinomakidneyneoplasm metastasisprognosisnomogramsMetricsAuthor Information Roberto Iacovelli Medical Oncology Unit 1, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy More articles by this author Alessio Farcomeni Department of Public Health and Infectious Diseases, Sapienza-University of Rome, Rome, Italy More articles by this author Cora N. Sternberg Department of Medical Oncology, San Camillo Forlanini Hospital, Rome, Italy More articles by this author Giacomo Cartenì Oncology Unit, A. Cardarelli Hospital, Naples, Italy More articles by this author Michele Milella Medical Oncology A, Regina Elena National Cancer Institute, Rome, Italy More articles by this author Matteo Santoni Department of Medical Oncology, Polytechnic University of the Marche Region, Ancona, Italy More articles by this author Linda Cerbone Department of Medical Oncology, San Camillo Forlanini Hospital, Rome, Italy More articles by this author Giuseppe Di Lorenzo Medical Oncology, Genitourinary Cancer Section, University Federico II, Naples, Italy More articles by this author Elena Verzoni Medical Oncology Unit 1, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy More articles by this author Cinzia Ortega Fondazione del Piemonte per l'Oncologia IRCC, Candiolo, Italy More articles by this author Roberto Sabbatini Oncology Division, Department of Oncology and Hematology, University of Modena e Reggio Emilia, Modena, Italy More articles by this author Riccardo Ricotta Falck Division of Oncology, Ospedale Niguarda Ca' Granda, Milan, Italy More articles by this author Caterina Messina Oncology Division, Ospedali Riuniti, Bergamo, Italy More articles by this author Vito Lorusso National Cancer Research Center, Istituto Tumori "Giovanni Paolo II", Bari, Italy More articles by this author Francesco Atzori Medical Oncology Unit, Azienda Ospedaliero Universitaria of Cagliari, Cagliari, Italy More articles by this author Fabio De Vincenzo Oncology and Hematology Unit, Humanitas Cancer Center, Istituto Clinico Humanitas, Rozzano, Italy More articles by this author Cosimo Sacco Oncology Unit, St Maria della Misericordia Hospital, Udine, Italy More articles by this author Francesco Boccardo University and IRCCS AOU-San Martino-IST, National Cancer Research Institute, Genoa, Italy More articles by this author Francesco Valduga Medical Oncology, St. Chiara Hospital, Trento, Italy More articles by this author Francesco Massari Medical Oncology, "G.B. Rossi" Academic Hospital, University of Verona, Verona, Italy More articles by this author Valentina Baldazzi Department of Medical Oncology; Santa Maria Annunziata Hospital, Florence, Italy More articles by this author Saverio Cinieri Medical Oncology and Breast Unit Department, Sen A. Perrino Hospital, Brindisi, Italy More articles by this author Alessandra Mosca Medical Oncology, Maggiore della Carità University Hospital, Novara, Italy More articles by this author Enzo Maria Ruggeri Oncology Unit, Belcolle Hospital, Viterbo, Italy More articles by this author Alfredo Berruti Medical Oncology, University of Brescia, Brescia, Italy More articles by this author Giuseppe Procopio Medical Oncology Unit 1, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy More articles by this author Expand All Advertisement PDF downloadLoading ...